| HIV/AIDS – Drug Pipeline Analysis and Market | | | | Multi-class Combination Products, Nucleoside Reverse |
| Forecasts to 2016" is an essential source of | | | | Transcriptase Inhibitors (NRTIs), CCR5 receptor |
| information and analysis on the global HIV/AIDS | | | | antagonists, HIV integrase inhibitors, Nucleoside |
| market. The report identifies the key trends shaping | | | | analogues, Viral entry inhibitors, Maturation inhibitors |
| and driving the global HIV/AIDS market. The report | | | | and Fusion Inhibitors. |
| also provides insight on the prevalent competitive | | | | - Analysis of the current and future market |
| landscape and the emerging players expected to | | | | competition in the global HIV/AIDS market. The key |
| bring significant shift in the market positioning of the | | | | market players covered Boehring Ingelheim, Achillion |
| existing market leaders. Most importantly, the report | | | | Pharmaceuticals, GlaxoSmithKline, Incyte and |
| provides valuable insight on the pipeline products | | | | Pharmasset, Shire Pharmaceuticals and Tibotec Virco |
| within the global HIV/AIDS sector. GlobalData | | | | - Insightful review of the key industry drivers, |
| estimated the HIV/AIDS market was worth $12 | | | | restraints and challenges. Each trend is independently |
| billion in 2009. The global Human Immunodeficiency | | | | researched to provide qualitative analysis of its |
| Virus (HIV) infection market will continue to grow | | | | implications. |
| between 2009 and 2016 at a slower rate due to a | | | | - The key topics covered include a strategic |
| series of patent expiries during this period. The | | | | competitor assessment, market characterization, |
| growth rate is likely to decline from 2012 onwards | | | | unmet needs and implications for the future HIV |
| due to the impact of the patent expiry of key drugs. | | | | AIDS market. |
| The market is characterized by a high unmet need of | | | | Reasons to buy |
| drugs which can cure the disease. Highly Active | | | | The report will enhance your decision making |
| Antiretroviral Therapy (HAART) which requires | | | | capability in a more rapid and time sensitive manner. |
| patients to take different classes of drugs has | | | | It will allow you to: |
| however succeeded in achieving near zero levels of | | | | - Develop and design your in-licensing and out-licensing |
| HIV in infected people. Increased uptake of HAART | | | | strategies through review of pipeline products and |
| and increasing awareness (which leads to increased | | | | technologies and by identifying companies with the |
| treatment seeking) will drive the market. The pipeline | | | | most robust pipeline. |
| for HIV is strong and consists of more than 250 | | | | - Develop business strategies by understanding the |
| molecules currently in development for various | | | | trends shaping and driving the global HIV/AIDS |
| disease segments. | | | | market. |
| This report is built using data and information sourced | | | | - Drive revenues by understanding key trends, |
| from proprietary databases, primary and secondary | | | | innovative products and technologies, market |
| research and in house analysis by GlobalData's team | | | | segments and companies likely to impact the global |
| of industry experts. | | | | HIV/AIDS market in future. |
| Scope | | | | - Formulate effective sales and marketing strategies |
| - Annualized global HIV/AIDS market revenues data | | | | by understanding the competitive landscape and by |
| from 2001 to 2009, forecast for seven years to | | | | analyzing the performance of various competitors. |
| 2016. | | | | - Identify emerging players with potentially strong |
| - Geographies covered in this report are the United | | | | product portfolio and create effective |
| States (US), the United Kingdom (UK), Italy, Spain, | | | | counter-strategies to gain competitive advantage. |
| Germany, France and Japan. | | | | - Organize your sales and marketing efforts by |
| - Pipeline analysis data providing a split across phases | | | | identifying the market categories and segments that |
| by mechanism of action, and the emerging trends. | | | | present maximum opportunities for consolidations, |
| The key classes of mechanism of action include HIV | | | | investments and strategic partnerships. |
| vaccines, Nonnucleoside Reverse Transcriptase | | | | - What's the next big thing in the global HIV/AIDS |
| Inhibitors (NNRTIs), Protease Inhibitors (PIs), | | | | market landscape? |